Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Other Non-current Assets
Long-term assets not reported separately.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Other Non-current Assets · Q4 FY2025 · quarter ended Dec 2025
Other non-current assets remains negative
Q4 FY2025 other non-current assets was $0, compared with $387.44K a year earlier.
Context
- Other non-current assets amounted to 0.0% of total assets at the end of Q4 FY2025, down 2.0 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 387.44K | +523.5% |
| FY2023 | 2023-12-31 | 62.14K | +1978.9% |
| FY2022 | 2022-12-31 | 2.99K | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Assets vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the 9th highest of 10, against a peer median of +29.5%.
- Other non-current assets amounts to 0.0% of total assets for NNNN, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $32.9M USD | +29.5% | +21.4% | 3.1% | |
| Mar 2026 | $13.91M USD | +70.2% | +30.9% | 2.6% | |
| Feb 2026 | $10.5M USD | +8.4% | -1.7% | 4.0% | |
| Mar 2026 | $4.27M USD | +102.2% | +112.2% | 3.1% | |
| Mar 2026 | CA$2.51M CAD | -36.0% | -19.2% | 0.2% | |
| Dec 2025 | $2.37M USD | — | — | 0.7% | |
| Mar 2026 | $2.36M USD | +55.5% | +43.9% | 0.5% | |
| Mar 2026 | $1.65M USD | +1012.2% | +43.1% | 1.8% | |
| Mar 2026 | $398K USD | +28.4% | -15.7% | 0.3% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | -100.0% | — | 0.0% |
| Mar 2026 | -$1.84B USD | -239.2% | +10.5% | 14.0% | |
| Peer median (excluding NNNN) | — | +29.5% | +21.4% | 2.2% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.